OmniSeq is seeking a MD/DO-licensed Molecular Pathologist, licensed to practice medicine in New York State or with the ability to obtain a NYS license. The applicant will direct a CLIA CAP and NYS state-of- the-art next generation sequencing (NGS) laboratory.
The applicant will have the opportunity to sign out multiple types of NGS assays, including both DNA-seq and RNA-seq, as well as participate in the development of future assays. Clinically, the current need is to actively participate in both genomic and immune-oncology NGS solid tumor profiling assays that support physician decision making for both targeted therapies and immunotherapies. From a translational perspective, there is significant opportunity to participate in R&D of future NGS assays that will allow for high impact publications as well as multiple speaking opportunities.
The applicant will participate in clinical sign-out as well as develop a translational biomarker program with an emphasis on both genomics and immunology. Numerous opportunities exist for collaborative research with other clinicians and basic scientists at RPCI and OmniSeq’s other research partners.
OmnSeq's vision is to find the right drug or the right clinical trial for every patient. Founded in 2015, our mission is to deliver superior results by improving access to better cancer treatment options through comprehensive molecular profiling. OmniSeq is a subsidiary of Roswell Park Cancer Institute (RPCI) in Buffalo, New York. The company emerged from the RPCI Center of Personalized Medicine.
RPCI was the first institution to focus exclusively on cancer research and continues to be at the center of groundbreaking cancer research for more than a century. This includes initiating the first experiments in chemotherapy in 1904, becoming America’s First Comprehensive Cancer Center and providing the source — RP11 (RP stands for Roswell Park) — for much of the BAC clone library used in the Human Genome Project. The breakthrough research, scientific expertise, and commitment to improving patient care is the foundation of OmniSeq today. Visit http://www.omniseq.com to learn more.
Candidates must have or be eligible for: New York State full licensure (MD/DO), American Board of Pathology Certification in Molecular Pathology or American Board of Medical Genetics and Genomics (ABMGG) and New York State Certificate of Qualification, qualifications in Oncology (molecular and cellular tumor markers). The preferred candidate will have molecular pathology fellowship training, prior experience in molecular diagnostics, and/or experience or training in next generation sequencing for cancer testing will be given preference. Knowledge of Informatics a plus. Experience with Laboratory Information Systems, CLIMS and informatics solutions preferred.
Position is designated on-site and not available as remote.
Candidates must be eligible to work in the U.S., as sponsorship is NOT available.
To apply, please forward your resume to Colleen Scharf, VP of Operations at email@example.com